TransCode Therapeutics Reports Progress In Early-Stage Study For Lead Cancer Drug
benzinga.com/general/biotech/25/05/45133523/exclusive-transcode-therapeutics-reports-progress-in-early-stage-study-for-lead-cancer-drug
TransCode Therapeutics, Inc. (NASDAQ:RNAZ) announced further progress on Thursday in its Phase 1a clinical trial of TTX-MC138 in patients with metastatic cancer.
To date, 13 patients have received at least one dose of TTX-MC138 at four separate dose levels ranging from 0.8 mg/kg to 4.8…
This story appeared on benzinga.com, 2025-05-01 12:32:30.